PUBLISHER: Grand View Research | PRODUCT CODE: 1300974
PUBLISHER: Grand View Research | PRODUCT CODE: 1300974
The global thrombosis and hemostasis biomarkers market size is expected to reach USD 7.92 Billion by 2030, expanding at a CAGR of 5.90% from 2023 to 2030. The rapid growth of the market is attributable to factors such as the increasing prevalence of chronic diseases such as pancreatic cancer, the rise in the geriatric population, the growing demand for personalized medicines, and advancements in technology.
The thrombosis & hemostasis biomarkers industry has grown significantly in recent years, with changes in adoption patterns and the introduction of novel technologies. The increasing trend of adopting POC analyzers in the market is creating traction for small-sized analyzers. Increasing research on mini- and microdevices is anticipated to continue over the coming years. For instance, in June 2022, Dr. Arnold Lining Ju announced the development of a microdevice that can detect blood clots and can be used to detect early signs of a heart attack.
The prevalence of chronic diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and pancreatic cancer is anticipated drive the need for thrombosis & hemostasis biomarkers to detect the probability of hemostasis. Chronic diseases have a tendency to damage blood vessels, leading to the formation of clots that can block blood flow and cause serious health complications, such as stroke & heart attack. For instance, pulmonary embolism (PE), is a serious medical condition that occurs in the legs and travels to the lung, obstructing blood flow.
As per American Lung Association, in January 2023, PE affected nearly 900,000 people in the U.S. and nearly 33% of the people affected by (DVT) or pulmonary embolism (PE) experience recurrence of PE in ten years. Therefore, high prevalence and significant repetition of cases will lead to an increase in the demand for thrombosis & hemostasis biomarkers.
Furthermore, key players operating in the market are focusing on different forms of strategic initiatives such as mergers and acquisitions to increase their respective position in the thrombosis & hemostasis biomarkers industry. For instance, in January 2023, Thermo Fisher Scientific, Inc., announced a partnership with AstraZeneca to manufacture a blood-based and solid tissue companion diagnostic test for Tagrisso. This was expected to propel the thrombosis and hemostasis biomarkers industry. Additionally, in May 2022, Quidel Corporation acquired Ortho Clinical Diagnostics for USD 6 billion. The new company was named QuidelOrtho. Through this acquisition, Quidel gained access to Ortho Clinical Diagnostics' biomarker tests portfolio.